Last-Resort drug access opens for severe HS patients
NCT ID NCT05583604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides access to secukinumab (AIN457) for people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or have exhausted all available therapies. Doctors must request access on behalf of their patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection tame the painful lumps of hidradenitis suppurativa?
- Can brain scans reveal the hidden toll of hidradenitis suppurativa?
- Could botox calm the painful skin flares of hidradenitis suppurativa?
- Can Real-World data unlock better skin disease care?
- Foam could ease painful skin lumps in hidradenitis suppurativa
- Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care